Androgen receptor (AR) expression in prostate cancer and progression of the tumor: Lessons from cell lines, animal models and human specimens

Steroids

Volumn 77, Issue 10, 2012, Pages 996-1001

  Tamburrino, Lara ^a   Salvianti, Francesca ^a   Marchiani, Sara ^a   Pinzani, Pamela ^a   Nesi, Gabriella ^a   Serni, Sergio ^a   Forti, Gianni ^a   Baldi, Elisabetta ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Androgen receptor; Laser microdissection; Progression; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR;

APOPTOSIS; CANCER CELL CULTURE; CASTRATION RESISTANT PROSTATE CANCER; CONFERENCE PAPER; DISEASE MODEL; EXPERIMENTAL MODEL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN EXPRESSION; STROMA; TRANSURETHRAL RESECTION; TUMOR GROWTH; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN;

ANIMALIA;

EID: 84863981962     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2012.01.008     Document Type: Conference Paper

References (68)

1. G. Corona, E. Baldi, and M. Maggi Androgen regulation of prostate cancer: where are we now? J Endocrinol Invest 34 2011 232 243
2. P. Giovannelli, M. Di Donato, T. Giraldi, A. Migliaccio, G. Castoria, and F. Auricchio Targeting rapid action of sex steroid receptors in breast and prostate cancers Front Biosci 17 2011 2224 2232
3. C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, and R. Vessella Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39 (Pubitemid 38524696)
4. P. Mathew Prolonged control of progressive castration-resistant metastatic prostate cancer with testosterone replacement therapy: the case for a prospective trial Ann Oncol 19 2008 395 396 (Pubitemid 351201727)
5. M.J. Morris, D. Huang, W.K. Kelly, S.F. Slovin, R.D. Stephenson, and C. Eicher Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer Eur Urol 56 2009 237 244
6. J.R. Zhou, L. Yu, L.F. Zerbini, T.A. Libermann, and G.L. Blackburn Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations Int J Cancer 110 2004 800 806 (Pubitemid 38758504)
7. R.B. Marques, W.M. van Weerden, S. Erkens-Schulze, C.M. de Ridder, C.H. Bangma, and J. Trapman The human PC346 xenograft and cell line panel: a model system for prostate cancer progression Eur Urol 49 2006 245 257 (Pubitemid 43197860)
8. M.J. Linja, K.J. Savinainen, O.R. Saramäki, T.L. Tammela, R.L. Vessella, and T. Visakorpi Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer Cancer Res 61 2001 3550 3555 (Pubitemid 32694958)
9. H. Kinoshita, Y. Shi, C. Sandefur, L.F. Meisner, C. Chang, and A. Choon Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer Cancer Res 60 2000 3623 3630 (Pubitemid 30482185)
10. S. Marchiani, L. Tamburrino, G. Nesi, M. Paglierani, S. Gelmini, and C. Orlando Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation Int J Androl 33 2010 784 793
11. Hong SK, Kim JH, Lin MF, Park JI. The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signalling via androgen receptor downregulation in prostate cancer cells. Exp Cell Res 2011 [Epub ahead of print].
12. M.E. Wright, M.J. Tsai, and R. Aebersold Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells Mol Endocrinol 17 2003 1726 1737 (Pubitemid 37072290)
13. L. Bonaccorsi, V. Carloni, M. Muratori, A. Salvadori, A. Giannini, and M. Carini Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype Endocrinology 141 2000 3172 3182 (Pubitemid 32269005)
14. A. Evangelou, M. Letarte, A. Marks, and T.J. Brown Androgen modulation of adhesion and antiadhesion molecules in PC-3 prostate cancer cells expressing androgen receptor Endocrinology 143 2002 3897 3904 (Pubitemid 35244369)
15. L.E. Heisler, A. Evangelou, A.M. Lew, J. Trachtenberg, H.P. Elsholtz, and T.J. Brown Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor Mol Cell Endocrinol 126 1997 59 73 (Pubitemid 27055548)
16. Kobayashi M, Huang Y, Jin C, Luo Y, Okamoto T, Wang F, et al. FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells. Prostate 2011 [Epub ahead of print].
17. L.E. Lamb, J.C. Zarif, and C.K. Miranti The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-κB and Bcl-xL Independently of PI3Ksignaling Cancer Res 71 2011 2739 2749
18. B. Cinar, K.S. Koeneman, M. Edlund, G.S. Prins, H.E. Zhau, and L.W. Chung Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line Cancer Res 61 19 2001 7310 7317 (Pubitemid 32946530)
19. R. Davis, D. Jia, B. Cinar, S.C. Sikka, K. Moparty, and H.E. Zhau Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation Biochem Biophys Res Commun 309 2003 937 945 (Pubitemid 37122620)
20. J. Nightingale, K.S. Chaudhary, P.D. Abel, A.P. Stubbs, H.M. Romanska, and S.E. Mitchell Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells Neoplasia 5 2003 347 361 (Pubitemid 37048612)
21. V. Guerini, D. Sau, E. Scaccianoce, P. Rusmini, P. Ciana, and A. Maggi The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype Cancer Res 65 2005 5445 5453 (Pubitemid 40827358)
22. Y. Niu, S. Altuwaijri, K.P. Lai, C.T. Wu, W.A. Ricke, and E.M. Messing Androgen receptor is a tumor suppressor and proliferator in prostate cancer Proc Natl Acad Sci USA 105 2008 12182 12187
23. L. Bonaccorsi, V. Carloni, M. Muratori, L. Formigli, S. Zecchi, and G. Forti EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR) Int J Cancer 112 2004 78 86 (Pubitemid 39249494)
24. L. Bonaccorsi, D. Nosi, M. Muratori, L. Formigli, G. Forti, and E. Baldi Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines J Mol Endocrinol 38 2007 51 66 (Pubitemid 46351592)
25. A. Hatzoglou, M. Kampa, C. Kogia, I. Charalampopoulos, P.A. Theodoropoulos, and P. Anezinis Membrane androgen receptor activation induces apoptotic regression of human prostate cancer cells in vitro and in vivo J Clin Endocrinol Metab 90 2005 893 903 (Pubitemid 40279214)
26. N. Papadopoulou, I. Charalampopoulos, K. Alevizopoulos, A. Gravanis, and C. Stournaras Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells Exp Cell Res 314 2008 3162 3174
27. N. Papadopoulou, I. Charalampopoulos, V. Anagnostopoulou, G. Konstantinidis, M. Föller, and A. Gravanis Membrane androgen receptor activation triggers down-regulation of PI-3K/Akt/NF-kappaB activity and induces apoptotic responses via Bad, FasL and caspase-3 in DU145 prostate cancer cells Mol Cancer 7 2008 88
28. M. Kampa, C. Kogia, P.A. Theodoropoulos, P. Anezinis, I. Charalampopoulos, and E.A. Papakonstanti Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells Mol Cancer Ther 5 2006 1342 1351 (Pubitemid 43881328)
29. M. Kampa, K. Theodoropoulou, F. Mavromati, V. Pelekanou, G. Notas, and E.D. Lagoudaki Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer J Pharmacol Exp Ther 337 2011 24 32
30. Y. Sheng-Qiang, K.-P. Lai, S.-J. Xia, H.-C. Chang, C. Chang, and S. Yeh The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer Asian J Androl 11 2009 39 48
31. S. Minner, M. Enodien, H. Sirma, A.M. Luebke, A. Krohn, and P.S. Mayer ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy Clin Cancer Res 17 2011 5878 5888
32. C. Dambaki, C. Kogia, M. Kampa, K. Darivianaki, M. Nomikos, and P. Anezinis Membrane testosterone binding sites in prostate carcinoma as a potential new marker and therapeutic target: study in paraffin tissue sections BMC Cancer 5 2005 148
33. A. Fleischmann, C. Rocha, S. Schobinger, R. Seiler, B. Wiese, and G.N. Thalmann Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases Prostate 71 2011 453 460
34. S.D. Sweat, A. Pacelli, E.J. Bergstralh, J.M. Slezak, L. Cheng, and D.G. Bostwick Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery J Urol 161 1999 1233 1237 (Pubitemid 29426124)
35. M.J. Donovan, I. Osman, F.M. Khan, Y. Vengrenyuk, P. Capodieci, and M. Koscuiszka Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease BJU Int 105 2010 462 467
36. E. Hörnberg, E.B. Ylitalo, S. Crnalic, H. Antti, P. Stattin, and A. Widmark Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival PLoS One 6 2011 e19059
37. S.A. Tomlins, D.R. Rhodes, S. Perner, S.M. Dhanasekaran, R. Mehra, and X.W. Sun Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648 (Pubitemid 41528150)
38. L. Bonaccorsi, G. Nesi, F. Nuti, M. Paglierani, C. Krausz, and L. Masieri Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results J Endocrinol Invest 32 2009 590 596
39. J.P. Clark, and C.S. Cooper ETS gene fusions in prostate cancer Nat Rev Urol 6 2009 429 439
40. Valkenburg KC, Williams BO. Mouse models of prostate cancer. Prostate Cancer 2011; Article ID 895238, 22 pages.
41. Y. Niu, S. Altuwaijri, S. Yeh, K.P. Lai, S. Yu, and K.H. Chuang Targeting the stromal androgen receptor in primary prostate tumors at earlier stages Proc Natl Acad Sci USA 105 2008 12188 12193
42. Y. Niu, T.M. Chang, S. Yeh, W.L. Ma, Y.Z. Wang, and C. Chang Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails Oncogene 29 2010 3593 3604
43. I.L. Rosner, L. Ravindranath, B. Furusato, Y. Chen, C. Gao, and J. Cullen Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy Urology 70 2007 1225 1229 (Pubitemid 350297391)
44. T.J. Walton, G. Li, T.A. McCulloch, R. Seth, D.G. Powe, and M.C. Bishop Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue Prostate 69 2009 810 819
45. P. Pinzani, K. Lind, F. Malentacchi, G. Nesi, F. Salvianti, and D. Villari Prostate-specific antigen mRNA and protein levels in laser microdissected cells of human prostate measured by real-time reverse transcriptase-quantitative polymerase chain reaction and immuno-quantitative polymerase chain reaction Hum Pathol 39 2008 1474 1482
46. A.M. Traish, and H.H. Wotiz Prostatic epidermal growth factor receptors and their regulation by androgens Endocrinology 121 1987 1461 1467 (Pubitemid 17155896)
47. P. Hammarsten, S.H. Rudolfsson, R. Henriksson, P. Wikström, and A. Bergh Inhibition of the epidermal growth factor receptor enhances castration-induced prostate involution and reduces testosterone-stimulated prostate growth in adult rats Prostate 67 2007 573 581 (Pubitemid 46685276)
48. A.M. Traish, and A. Morgentaler Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth Br J Cancer 101 2009 1949 1956
49. J.C. Pignon, B. Koopmansch, G. Nolens, L. Delacroix, D. Waltregny, and R. Winkler Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines Cancer Res 69 2009 2941 2949
50. B.S. Carver, C. Chapinski, J. Wongvipat, H. Hieronymus, Y. Chen, and S. Chandarlapaty Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer Cancer Cell 19 2011 575 586
51. C.P. Chuu, J.M. Kokontis, R.A. Hiipakka, J. Fukuchi, H.P. Lin, and C.Y. Lin Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer J Biomed Sci 18 2011 63 74
52. H. Takeda, K. Akakura, M. Masai, S. Akimoto, R. Yatani, and J. Shimazaki Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma Cancer 77 1996 934 940 (Pubitemid 26061289)
53. N. Segawa, I. Mori, H. Utsunomiya, M. Nakamura, Y. Nakamura, and L. Shan Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer Pathol Int 51 2001 452 459 (Pubitemid 32646211)
54. L.P. Pertschuk, H. Schaeffer, J.G. Feldman, R.J. Macchia, Y.D. Kim, and K. Eisenberg Immunostaining for prostate cancer androgen receptor in paraffin identifies a subset of men with a poor prognosis Lab Invest 73 1995 302 305
55. T. Inoue, T. Segawa, T. Shiraishi, T. Yoshida, Y. Toda, and T. Yamada Androgen receptor, Ki67, and P53 expression in radical prostatectomy specimens predict treatment failure in Japanese population Urology 66 2005 332 337 (Pubitemid 41138093)
56. R. Li, T. Wheeler, H. Dai, A. Frolov, T. Thompson, and G. Ayala High level of androgen receptor is associated with aggresseve clinicopathologic features and decreased biochemical recurrence-free survival in prostate Am J Surg Pathol 28 2004 928 934 (Pubitemid 38856850)
57. S.M. Henshall, D.I. Quinn, C.S. Lee, D.R. Head, D. Golovsky, and P.C. Brenner Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer Cancer Res 61 2001 423 427 (Pubitemid 32128590)
58. M.A. Noordzij, J.F. Bogdanowicz, C. van Krimpen, T.H. van der Kwast, and G.J. van Steenbrugge The prognostic value of pretreatment expression of androgen receptor and bcl-2 in hormonally treated prostate cancer patients J Urol 158 1997 1880 1884
59. Rades D, Setter C, Dahl O, Schild SE, Noack F. The prognostic impact of tumor cell expression of estrogen receptor-α, progesterone receptor, and androgen receptor in patients irradiated for non-small cell lung cancer. Cancer 2011 [Epub ahead of print].
60. M.V. Sadi, and E.R. Barrack Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy Cancer 71 1993 2574 2580 (Pubitemid 23100494)
61. J.R. Sterbis, C. Gao, B. Furusato, Y. Chen, S. Shaheduzzaman, and L. Ravindranath Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival Clin Cancer Res 14 2008 758 763 (Pubitemid 351231157)
62. V.E. Theodoropoulos, A. Tsigka, A. Mihalopoulou, V. Tsoukala, A.C. Lazaris, and E. Patsouris Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications Urology 66 2005 897 902 (Pubitemid 41440864)
63. Y.Q. Qiu, I. Leuschner, and P.M. Braun Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review Asian J Androl 10 2008 855 863
64. K.K. Miyamoto, S.A. Mcsherry, G.A. Dent, M. Sar, E.M. Wilson, and F.S. French Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue J Urol 149 1993 1015 1019 (Pubitemid 23133761)
65. G. Schatzl, S. Madersbacher, A. Haitel, A. Gsur, M. Preyer, and G. Haidinger Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer J Urol 169 2003 1312 1315 (Pubitemid 36323774)
66. J.A. Ruizeveld de Winter, J. Trapman, A.O. Brinkmann, W.J. Boersma, E. Mulder, and F.H. Schroeder Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry J Pathol 160 1990 329 332 (Pubitemid 20136759)
67. K.E. Gaston, D. Kim, S. Singh, O.H. Ford 3rd, and J.L. Mohler Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer J Urol 170 2003 990 993 (Pubitemid 36999618)
68. O.H. Ford, C.W. Gregory, D. Kim, A.B. Smitherman, and J.L. Mohler Androgen receptor gene amplification and protein expression in recurrent prostate cancer J Urol 170 2003 1817 1821 (Pubitemid 37254935)